Compare DraftKings Inc (DKNG) vs Novavax Inc (NVAX) Price & Performance

DraftKings (DKNG) trades at $19.15, down 3.04% and near its 52-week low of $18.95. The stock is technically bearish with weak moving averages, though RSI indicates potential oversold conditions. Fundamentally, revenue grew to $6.05B in 2025 with a slight net profit of $3.71M, but recent quarters show earnings misses. The company is investing in prediction markets and maintains a $1B EBITDA target for 2026.

Despite a high valuation (P/E 246.33) and recent price decline, 75% of analysts rate DKNG a Buy with a $33.13 consensus target. Key risks include competitive pressure, regulatory uncertainty, and the stock's sensitivity to growth expectations. The path to sustained profitability and margin expansion remains critical for investor confidence.

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.

The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.